Do you have #metastatic #BreastCancer and a new prescription for a CDK4/6 inhibitor? If so, you may be eligible to participate in #ClinicalTrial EAQ221CD/CONCURxP. Learn more here: https://bit.ly/EAQ221CD #bcsm cc: @GelarehSadigh, @ilana_graetz
.@Dr_AmerZeidan of @SmilowCancer & @YaleCancer is leading clinical study EA9171, testing if adding a new drug to the usual treatment for chronic myelogenous #leukemia could help patients. Learn more: https://bit.ly/ea9171-study #CML #leusm
The EAF223/GABLE clinical study is testing different imaging techniques that could help make better predictions about #BrainCancer progression. Learn more here: https://bit.ly/gable-trial
cc: @DukeRadiology, @glioblastf, @gbmfoundation
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
Active Clinical Trials
Participating Institutions
International Sites
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).